Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

Kushnir, Christina

364 - Poster Session B
Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

Sunday, March 23, 2014: 2:20 PM

West Exhibit Hall (Tampa Convention Center)

C. L. Kushnir¹, K. Frick², Z. Zhao² and R. L. Giuntoli II¹
¹Johns Hopkins Medical Institutions, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

364 - Poster Session B
Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

364 - Poster Session B Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

364 - Poster Session B
Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?